BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The discovery that imatinib effectively treats CML harboring the BCR-ABL fusion protein [134] led to the drug’s FDA approval in 2001 [135], demonstrated the utility of targeted cancer therapy [136,137], kindled enthusiasm for the identification of other genetically vulnerable cancers and their treatments [90,138] and underscored the clinical value and potential of precision oncology [98,139,140].